AI-generated · cited to primary sources · not investment advice · How we research
Our verdict on Apollo Hospitals isn’t the consensus take — see where we landed, and the one risk the bull case glosses over.
See the verdict — free →Continue evaluating bolt-on acquisitions in selected Tier-1 cities and metros. (+1 more commitment)
“Continue to evaluate bolt-on acquisitions in select Tier -1 cities & Metros”
Management's growth mix aspiration for organic hospital growth is approximately half volume and half case mix and pricing. — target: For 12%–14% organic growth, approximately half from volume and half from case mix and pricing (+1 more commitment)
“So we would like to believe that when it is a 12%, 13% organic growth that we look at of 14%, we would like to be half on the volume and the balance half on combination of case mix and pricing.”
Apollo expects to maintain cash-plus-insurance payer mix at approximately 85%, including as it expands outside southern India. — target: Approximately 85%
“I think 85% is very maintained.”
Management expects Bangladesh patient volumes to recover, with at least 60% having returned in October, and is exploring additional international markets including Uzbekistan, Africa, Indonesia and Iraq. — target: At least 60% of Bangladesh patients returning
“Bangladesh, at least 60% has started coming back in October and we believe that we will mitigate the impact of losing one territory. Also, we are exploring new markets, including the Northern markets in Uzbekistan, etcetera. So those that are surrounding markets, Africa, some with Indonesia, Iraq.”
Apollo intends to continue strengthening clinical programs and high-acuity specialties, including oncology, robotics and advanced care pathways. (+1 more commitment)
“Alongside capacity expansion, we continue to deepen our clinical leadership through investments in high acuity specialties, oncology, robotics and advanced care pathways.”
See the full cited Management analysis of Apollo Hospitals
The presentation shows a broad Indian footprint across metros and non-metros and plans substantial capacity growth: about 3,657 census beds are planned over five years, taking census capacity from 9,483 to approximately 13,100. It does not provide regional revenue shares, so a revenue-based geographic shift cannot be measured. (5 expanding)
“Overall Total ... 77 ... Capacity Census Beds 11,147 ... Operational Census Beds 9,857”
The Bangladesh patient reduction lowered Healthcare Services revenue by about 1% in Q2 FY26. Management said at least 60% of Bangladesh patient volumes had begun returning by October and described exploring other international markets, including Uzbekistan, Africa, Indonesia and Iraq. The later baseline says Bangladesh volumes had recovered to 60%–70% of their former peak and international-patient revenue was up 26% YoY, supporting a favorable recovery and diversification direction. The transcript gives no international revenue share. (2 expanding)
“The reduction in number of patients from Bangladesh has had a 1% impact on Healthcare Services revenue in Q2 FY26.”
Apollo reported 16% year-on-year revenue growth in its focus specialties—cardiac, oncology, neurosciences, gastroenterology, orthopedics and transplant—in Q3 FY26. It also cited investment in technologies such as robotics and growth in high-end surgeries. The later baseline specifically reports robotic surgeries increased 85%, indicating further development of this clinical capability, but no comparable Q3 FY26 robotics growth figure is provided. (2 expanding)
“The 2 mobile gantries are more or less fully occupied. Sometimes very frequently, we are encountering a wait list”
Revenue per inpatient rose 9% year over year, indicating higher average spend per hospital admission. This is consistent with greater pricing and/or case complexity, though the presentation does not separate those effects. (5 expanding across 3 engines)
“Revenue 35,670 29,351 22% ... EBIT 6,820 5,610 22% ... margin (%) 19.1% 19.1% ... Healthcare Services Revenue grew by 22% in Q1FY27. Overall Volume grew by 13%.”
Apollo reported growing revenue from international patients, up 26% YoY. Management said patients come from 150 countries, but did not disclose the international revenue share, the domestic-versus-international split, or revenue by country. Bangladesh patient volumes had recovered to only 60%–70% of their former peak, so the international business was not fully back to that level.
“Revenue from international patients grew by 26% over the same quarter last year.”
See the full cited Business Model analysis of Apollo Hospitals
New capacity is beginning to contribute, with Sarjapur already open and Gurgaon scheduled to open during FY27. Gurgaon is expected to contribute more meaningfully from Q4 as patient volumes build; management also cautioned that new-hospital losses may rise during the ramp-up.
“Our 180-bed facility in Sarjapur, Bengaluru was operationalized this quarter. Gurgaon remains on track for operationalization in Q3 FY27.”
In Q3 FY26, Healthcare Services revenue grew 14% year on year, supported by 5% volume growth, 4% case-mix improvement and 5% pricing. Inpatient volumes grew 4.5% year on year in Q3, up from 2% in Q2, indicating an improving volume trend. The transcript gives average revenue per patient of ₹180,917 for Q3 versus ₹173,246 in Q2, but does not provide year-on-year growth for this metric. The stated revenue-growth target for existing hospitals is 12%–14%; new beds are expected to add a further 3%–4%. (5 accelerating across 5 signals)
“Healthcare Services Revenue grew by 22% in Q1FY27 . Overall Volume grew by 13%. (Established Units Volume grew by 11%, price of 4% and Case mix /payor mix of 3%). Average Revenue per In patient grew by 8% to ₹186,630 in Q1FY27.”
Healthcare Services revenue was ₹3,183 crore in Q3 FY26, up 14% year on year, while nine-month revenue was ₹9,287 crore, up 12%. Management sees 12%–14% growth from existing hospitals and expects the new beds to add another 3%–4%. Four new hospitals and the Pune ramp-up are expected to add about 1,500 beds in total, with roughly half operationalized in the coming fiscal year. New-unit losses are estimated at about ₹150 crore for the next year, and management expects the first 750 beds to reach about 40% occupancy in their first year. (1 steady, 1 new trend across 2 signals, 2 leading indicators)
“Commissioned 5 new hospitals (~1,000 Census beds) ... Of the total 1,000 Census beds, excluding Gurgaon, 380 beds have been operationalized, with the remaining 620 beds planned to be progressively activated over the next 12–18 months, in line with the phased ramp-up plan. Total Project Cost of ~₹11,150 crs with Balance to be spent of ~₹7,500crs. ... Grand Total 5,798 Total Beds 4,710 Census Beds ₹11,152 [crores].”
The transcript quantifies a 1% drag on Healthcare Services revenue from fewer Bangladeshi patients in Q2 FY26, while management said at least 60% of Bangladesh patients had started returning in October and it was exploring additional source markets. It does not report international-patient revenue growth, so the available evidence indicates a recovery in patient flow but not a comparable revenue trend. (1 new trend across 1 signal)
“Revenue from international patients grew by 26% over the same quarter last year. The volume growth was broad-based across the network and across all specialties.”
Apollo's complex-specialty portfolio continued to grow: cardiac, oncology, neurosciences, gastroenterology and orthopaedics together recorded 6% volume growth and 14% revenue growth in Q2 FY26. The transcript also reports 9% growth in average revenue per patient. With only one comparable period here, this is a new reported data point, not a proven multi-quarter acceleration. (4 new trend, 1 steady across 5 signals)
“Total inpatient volumes grew by 13% year-on-year with occupancy at 70%. Average revenue per patient increased by 8% year-on-year to INR 186,630. ... Congo-T volumes increased 15%, while revenues grew 24% year-on-year. These specialties now contribute to 62% of inpatient net revenues”
See the full cited Future Growth analysis of Apollo Hospitals
In the older Q2 FY26 presentation, Apollo planned 4,486 total beds, including 3,657 census beds, at an estimated cost of ₹8,294 crore, with about ₹5,800 crore still to spend. The later baseline reports a larger plan of about 4,710 census beds for roughly ₹11,150 crore, with about ₹7,500 crore remaining. The planned spend and remaining funding requirement therefore increased over time; no project-level contingency is disclosed in either assessment. Risk worsened from MEDIUM to HIGH. (5 intensifying, 1 high-severity)
“Total Project Cost of ~₹ 11,150 crs with Balance to be spent of ~₹7,500crs.”
The Nov 2025 call described a phased schedule for six hospitals: two starting in Q3, two in Q4, and two around Q1, with all census beds expected to be operational by the end of the next fiscal year. The Aug 2026 baseline still reports 620 of 1,000 census beds (excluding Gurgaon) as planned over the next 12–18 months, indicating that a substantial portion remained to be opened. The available figures do not establish whether the schedule slipped, since the earlier plan covered a different set and timing of beds; the risk remains, but direction versus the baseline cannot be reliably measured. (1 insufficient_data, 2 intensifying)
“Jubilee's expansion, there is some change in the configuration that we are planning, et cetera, so which is why it is moved to the next year. Secunderabad also, there was some delay because the landlord has taken some time to come back yet on the lease deed. So that is why there has been a delay.”
In the older Q3 FY26 period, management estimated about ₹150 crore of losses from new units in the coming fiscal year; only about ₹15 crore was included in reported results at that point. The Aug 2026 baseline reports ₹37.5 crore of new-unit start-up losses in Q1 FY27, confirming the ramp-up cost is material. Severity is therefore higher in the later period, although the quarterly figure is not directly comparable with the earlier full-year estimate. (3 intensifying, 1 emerging, 1 easing)
“Commissioned 5 New Hospitals in the last two quarters. New Units pre – operative expenses / losses in Q1FY27 is ₹ 375 mio.”
The older presentation shows insurance at 45% of inpatient payor mix in H1 FY26. The later baseline reports 46%. This small increase means exposure to insurer reimbursement and payment decisions is slightly greater; no management mitigation or insurer-specific collection data is disclosed. Severity remains MEDIUM. (2 intensifying, 1 stable, 2 insufficient_data)
“Inpatient Payor Mix ... Insurance 46%”
The hospital network remains reliant on international patients from Bangladesh for some volume recovery. Management said Bangladesh patient numbers are still well below their former peak, so renewed disruption could weaken demand, even though current patients are more complex cases. [CONCENTRATION]
“So, the volume has not reached that level. It is about 60% to 70% of what it used to be. But I would say that we are seeing patients with higher complexity, but for value, it is a little bit higher. But volume-wise, it is about 60% to 70% of what it used to be at its peak.”
See the full cited Risk analysis of Apollo Hospitals
Apollo Hospitals Healthcare Rally: Hospital Growth, ARPOB, Occupancy and 24|7 Profitability
12 Oct 2026Apollo Hospitals vs Fortis Healthcare: A Strategic Deep Dive into India's Leading Hospital Networks
21 Apr 2026Apollo Hospitals Investment Analysis: Evaluating India's Healthcare Leader for Long-Term Growth
20 Apr 2026Apollo Hospitals: The Blueprint for India's Healthcare Empire
30 Mar 2026AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.